RxDoctor Payments Data

Danny Curtis, MD

Radiation Oncology · Las Vegas, NVNPI 1528076130

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 11 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Siemens Medical Solutions USA, Inc. at 27.7% of the total. That places this record below the midpoint for radiation oncology clinicians in NV, where the typical reported total is $884.

$769in general payments, 2019–2025

Across 11 payments — averaging $69.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Siemens Medical Solutions USA, Inc.$213
  • Visionrt, Inc.$199
  • AstraZeneca$151
  • Regeneron Healthcare Solutions, Inc.$126
  • GSK$22
  • Sumitomo Pharma America, Inc.$22
  • plus $36 from 2 others
$228,114in research payments, 2019–2025

Across 9 payments — averaging $25,346 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AstraZeneca$228K

What the payments were for

  • Food & beverage$769100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$769 in reported general payments places this provider in the 40th percentile of 47 radiation oncology providers in Nevada.

See all radiation oncology providers in Nevada

Medicare billing

Part B allowed, 2024
$1,099,170
Medicare patients
246
Services billed
3,621

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dexamethasone27$611
Tamsulosin Hcl24$267

Paid to pharmacies, not to this prescriber.

Other radiation oncology in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →